Loss of phosphatase and tensin homolog enhances cell invasion and migration through aKT/Sp‐1 transcription factor/matrix metalloproteinase 2 activation in hepatocellular carcinoma and has clinicopathologic significance

Karen Man‐Fong Sze, Kris Lai‐Ting Wong, Glanice Kin‐Yan Chu, Joyce Man‐Fong Lee, Tai‐On Yau, Irene Oi‐Lin Ng – 11 February 2011 – Phosphatase and tensin homolog (PTEN) is frequently inactivated in cancers and is associated with advanced stages of cancers or metastasis. However, the molecular mechanism of PTEN in hepatocellular carcinoma (HCC) metastasis is unclear. In this study, we found frequent (47.5%, n = 40) protein underexpression of PTEN in human HCCs compared with their corresponding nontumorous livers.

Drug‐induced cholestasis

Manmeet S. Padda, Mayra Sanchez, Abbasi J. Akhtar, James L. Boyer – 11 February 2011 – Recent progress in understanding the molecular mechanisms of bile formation and cholestasis have led to new insights into the pathogenesis of drug‐induced cholestasis. This review summarizes their variable clinical presentations, examines the role of transport proteins in hepatic drug clearance and toxicity, and addresses the increasing importance of genetic determinants, as well as practical aspects of diagnosis and management. (HEPATOLOGY 2011;)

Hepatocyte‐targeted expression by integrase‐defective lentiviral vectors induces antigen‐specific tolerance in mice with low genotoxic risk

Janka Mátrai, Alessio Cantore, Cynthia C. Bartholomae, Andrea Annoni, Wei Wang, Abel Acosta‐Sanchez, Ermira Samara‐Kuko, Liesbeth De Waele, Ling Ma, Pietro Genovese, Martina Damo, Anne Arens, Kevin Goudy, Timothy C. Nichols, Christof von Kalle, Marinee K. L. Chuah, Maria Grazia Roncarolo, Manfred Schmidt, Thierry VandenDriessche, Luigi Naldini – 11 February 2011 – Lentiviral vectors are attractive tools for liver‐directed gene therapy because of their capacity for stable gene expression and the lack of preexisting immunity in most human subjects.

Intention‐to‐treat analysis of liver transplantation for hepatocellular carcinoma: Living versus deceased donor transplantation

Prashant Bhangui, Eric Vibert, Pietro Majno, Chady Salloum, Paola Andreani, Joao Zocrato, Philippe Ichai, Faouzi Saliba, Rene Adam, Denis Castaing, Daniel Azoulay – 11 February 2011 – For patients who have cirrhosis with hepatocellular carcinoma (HCC), living donor liver transplantation (LDLT) reduces waiting time and dropout rates. We performed a comparative intention‐to‐treat analysis of recurrence rates and survival outcomes after LDLT and deceased donor liver transplantation (DDLT) in HCC patients.

Hepatic encephalopathy: A central neuroinflammatory disorder?

Roger F. Butterworth – 11 February 2011 – Encephalopathy and brain edema are serious central nervous system complications of liver failure. Recent studies using molecular probes and antibodies to cell‐specific marker proteins have demonstrated the activation of microglial cells in the brain during liver failure and confirmed a central neuroinflammatory response.

Subscribe to